Gilead Sciences, (GILD) Financials
Gilead Sciences, (GILD) Historical Financial Statements and Key Metrics for 1996 - 2023
Full Gilead Sciences, financials for 1996 - 2023 are available in the
US Historical Financials dataset
All financial data is sourced direct from SEC 10-Q and 10-K filings, restatements are included.
Gilead Sciences, Income Statements
(in $ 000,000's)
| Quarter End | Revenue | Gross Profit | Operating Income | Net Income | EBITDA | EPS |
| 2023-Dec-31 | 7,115 | 5,555 (78.1 %) | 2,506 (35.2 %) | 1,429 (20.1 %) | 3,139 | 1.14 |
| 2023-Sep-30 | 7,050 | 5,485 (77.8 %) | 2,623 (37.2 %) | 2,180 (30.9 %) | 2,641 | 1.73 |
| 2023-Jun-30 | 6,599 | 5,157 (78.1 %) | 1,665 (25.2 %) | 1,045 (15.8 %) | 2,054 | 0.83 |
| 2023-Mar-31 | 6,352 | 4,951 (77.9 %) | 1,705 (26.8 %) | 1,010 (15.9 %) | 2,011 | 0.80 |
| 2022-Dec-31 | 7,389 | 5,993 (81.1 %) | 5,115 (69.2 %) | 1,640 (22.2 %) | 5,643 | 1.30 |
| 2022-Sep-30 | 7,042 | 5,647 (80.2 %) | 2,837 (40.3 %) | 1,789 (25.4 %) | 3,189 | 1.42 |
| 2022-Jun-30 | 6,260 | 4,818 (77.0 %) | 2,029 (32.4 %) | 1,144 (18.3 %) | 2,279 | 0.91 |
Full historical income statements for 1996 - 2023 is included in the
US Historical Financials dataset.
Gilead Sciences, Balance Sheets
(in $ 000,000's)
| Quarter End | Total Assets | Total Liabilities | Total Debt | Total Equity | Cash & Equivalents |
| 2023-Dec-31 | 62,125 | 39,376 | 24,987 | 22,749 | 8,428 |
| 2023-Sep-30 | 62,373 | 40,131 | 25,906 | 22,242 | 8,021 |
| 2023-Jun-30 | 62,337 | 41,243 | 26,600 | 21,094 | 8,001 |
| 2023-Mar-31 | 61,876 | 40,937 | 26,516 | 20,939 | 7,200 |
| 2022-Dec-31 | 63,171 | 41,962 | 25,230 | 21,240 | 6,385 |
| 2022-Sep-30 | 62,557 | 41,500 | 25,223 | 21,081 | 5,660 |
| 2022-Jun-30 | 62,870 | 42,655 | 26,216 | 20,236 | 5,663 |
Full historical balance sheet data for 1996 - 2023 is included in the
US Historical Financials dataset.
Gilead Sciences, Cash Flow Statements
(in $ 000,000's)
| Quarter End | Operating Cash Flow | Investing | Financing | Free Cash Flow |
| 2023-Dec-31 | 2,169 | -727 | -1,099 | 1,954 |
| 2023-Sep-30 | 1,756 | -229 | -1,518 | 1,756 |
| 2023-Jun-30 | 2,337 | -483 | -1,101 | 2,198 |
| 2023-Mar-31 | 1,744 | -826 | -1,406 | 1,635 |
| 2022-Dec-31 | 2,567 | -375 | -1,554 | 2,386 |
| 2022-Sep-30 | 2,863 | -713 | -2,118 | 2,706 |
| 2022-Jun-30 | 1,802 | -308 | -1,003 | 1,659 |
Full historical cash flow data for 1996 - 2023 is included in the
US Historical Financials dataset.
Gilead Sciences, Key Valuation and Operating Metrics
| Quarter End | Market Capitalization ($ 000,000's) |
Enterprise Value ($ 000,000's) |
Price/Earnings ($ 000,000's) |
Price/Sales ($ 000,000's) |
Price/Book ($ 000,000's) |
| 2023-Dec-31 | 101,100 | 120,002 | 14.21 | 17.69 | 4.44 |
| 2023-Sep-30 | 93,525 | 113,726 | 13.27 | 10.73 | 4.20 |
| 2023-Jun-30 | 96,260 | 117,156 | 14.59 | 23.03 | 4.56 |
| 2023-Mar-31 | 103,547 | 125,127 | 16.30 | 25.63 | 4.95 |
| 2022-Dec-31 | 107,484 | 127,302 | 14.55 | 16.38 | 5.06 |
| 2022-Sep-30 | 77,421 | 97,945 | 10.99 | 10.82 | 3.67 |
| 2022-Jun-30 | 77,633 | 99,110 | 12.40 | 16.97 | 3.84 |
Full historical valuation and operating metrics for 1996 - 2023 are included in the
US Historical Financials dataset.